Journal
DRUGS
Volume 80, Issue 5, Pages 509-512Publisher
ADIS INT LTD
DOI: 10.1007/s40265-020-01287-y
Keywords
-
Categories
Ask authors/readers for more resources
Teprotumumab (teprotumumab-trbw; TEPEZZA (TM) - Horizon Therapeutics) is a monoclonal antibody insulin-like growth factor-I receptor (IGF-IR) antagonist developed for the treatment of thyroid eye disease (Graves ophthalmopathy/orbitopathy, thyroid-associated ophthalmopathy). Based on positive results from two multinational clinical trials teprotumumab was recently approved for this indication in the US. This article summarizes the milestones in the development of teprotumumab leading to this first approval for thyroid eye disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available